Seagen And Nurix Hope To Pioneer A New Class Of Degrader-Antibody Conjugates
The two drug developers announced a collaboration to develop and commercialize multiple cancer programs. Nurix will receive $60m up front.
The two drug developers announced a collaboration to develop and commercialize multiple cancer programs. Nurix will receive $60m up front.